Bridging the Gap: Revolutionizing Sumatriptan Succinate Delivery with Novel Mucoadhesive Polymer Possessing Dual Functionality
Tejinder K Marwaha, Ashwini Madgulkar, Mangesh BhalekarAim:
This research endeavors to investigate the multi-faceted characteristics of chitosan- 2-mercapto benzoic acid polymer and to provide empirical evidence supporting its suitability as a carrier for mucosal drug delivery applications.
Background:
Recent advancements in the development of mucoadhesive polymers have enabled the enhancement of gastrointestinal (GI) residence time and controlled release profiles for various dosage forms. In this study, a novel chitosan derivative, chitosan-2-mercapto benzoic acid, was used as a mucoadhesive polymer to formulate a sustained-release dosage form designed to improve the oral bioavailability of sumatriptan succinate, a therapeutically relevant compound.
Objective:
Sumatriptan succinate, a widely used antimigraine agent, exhibits limited therapeutic efficacy due to its compromised oral bioavailability (15%) and significant first-pass metabolism. To overcome these limitations, this study aimed to improve the oral bioavailability and permeability of sumatriptan succinate by exploiting a novel polymer-based formulation. In this investigation, a mucoadhesive buccal patch consisting of dual functionalized thiomer was designed, which delivered the medication throughout the requisite duration, preventing first-pass metabolism to the extent possible.
Methods:
A novel mucoadhesive buccal patch was designed for the systemic delivery of sumatriptan succinate via the buccal route, utilizing a novel dual-functionalized thiolated mucoadhesive polysaccharide polymer, chitosan-2-mercaptobenzoic acid. Formulations were developed by solvent evaporation technique and optimized using a 33 Box Behnken design with HPMC E15, chitosan, and propylene glycol concentrations as variables and their effect on drug release and mucoadhesive strength was studied.
Results:
FTIR and DSC analysis did not show any interaction between the drug and polymers. When compared to the drug, the thiomer patch and chitosan patch improved drug permeation by 2.5 and 1.3 times, respectively. Mucoadhesion and pharmacokinetic studies showed that thiomer containing buccal patch administration resulted in two-fold increased levels as compared to chitosan patch. The AUC0–5h in buccal therapy with thiomer was nearly equivalent to two-fold greater than the control, with a relative bioavailability of 282.47 percent.
Conclusions:
Thus, we can conclude that this study confirms the possibility of buccal patch as a viable and alternative form of effective sumatriptan succinate delivery rendering it a novel approach in pharmaceutical delivery systems for migraine treatment.